Aina Karen Anthi
- PhD student
Publications 2026
A human erythropoietin-albumin fusion protein tailored for enhanced plasma half-life and delivery across mucosal surfaces
Nat Commun, 17 (1)
DOI 10.1038/s41467-026-78243-z, PubMed 42951888
A modular nucleic acid-albumin biomolecular platform for multifunctional drug designs
J Control Release, 115514 (in press)
DOI 10.1016/j.jconrel.2026.115514, PubMed 42962825
Fusion of IgG antibodies to albumin inhibits transport across the placenta
Sci Immunol, 11 (122), eaee5151
DOI 10.1126/sciimmunol.aee5151, PubMed 42600043
Publications 2025
An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models
Nat Commun, 16 (1), 3999
DOI 10.1038/s41467-025-59353-6, PubMed 40312392
Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction
J Biol Chem, 301 (6), 108508
DOI 10.1016/j.jbc.2025.108508, PubMed 40222546
Publications 2024
Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria
Nat Commun, 15 (1), 2007
DOI 10.1038/s41467-024-46321-9, PubMed 38453922
Publications 2023
A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery
PNAS Nexus, 2 (12), pgad403
DOI 10.1093/pnasnexus/pgad403, PubMed 38077689
Publications 2021
The neonatal Fc receptor in mucosal immune regulation
Scand J Immunol, 93 (2), e13017
DOI 10.1111/sji.13017, PubMed 33351196